Background {#Sec1}
==========

Worldwide, lung cancer harbored the highest incidence and mortality rates among all malignant cancers \[[@CR1], [@CR2]\]. Non-small cell lung cancer (NSCLC), as the most common type of lung cancer, accounts for 75--80 % of all lung cancer cases \[[@CR3]\]. The development of lung cancer was greatly affected by the environmental factors, such as cigarette smoking, alcohol drinking and air pollutants \[[@CR4]--[@CR6]\]. However, evidence has showed that the genetic variants of cancer-related genes are associated with lung risk, which the important role of genetic factors in the development of lung cancer \[[@CR7]--[@CR9]\].

Nucleotide excision repair (NER) is the major DNA repair pathway to remove bulky DNA lesions induced by UV light and environmental carcinogens \[[@CR10]\]. NER has two subpathways, global genome NER (GG-NER) and transcription coupling NER (TC-NER). TC-NER is involved in a rapid removal of the damages on the transcribed strands of active genes and a resumption of transcription \[[@CR11]--[@CR13]\]. TC-NER is initiated by arresting RNA polymerase II at DNA lesion site on transcript strand. In the initiation of transcription coupling repair, the TC-NER specific proteins Cockayne syndrome complementation group A (CSA) and group B (CSB) are thought to play an important role in removing the stalled RNA polymorase II and recruiting other DNA repair proteins \[[@CR14]\]. Many studies have demonstrated that the decreased expression of CSA and CSB in lung cancer and the genetic variants in these two genes were associated with the lung cancer risk \[[@CR15]--[@CR18]\].

Xeroderma pigmentosum group A (XPA)-binding protein 2 (XAB2), which located at 19p13.2, was first identified as an interacting protein with XPA and hence found to interact with CSA, CSB and RNA polymerase II to participant to TC-NER and transcription \[[@CR17], [@CR19], [@CR20]\]. *In vitro*, when cells treated with DNA-damaging agents, enhanced interaction of XAB2 with RNA polymerase II or XPA was observed, which suggesting DNA damage-responsive activity of the XAB2 \[[@CR19]\].

Due to the important role of *XAB2* in the TC-NER, we proposed that the genetic variants in *XAB2* genes might contribute to the risk of lung cancer. To verify this proposal, we conducted this case-control study to evaluate the role of *XAB2* tagSNPs in the development of NSCLC.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The study population has been described previously \[[@CR21]\]. Briefly, this hospital-based case-control study consisted of 470 patients with NSCLC and 470 cancer-free controls. All subjects were unrelated Han Chinese. All patients with newly diagnosed, and previously untreated primary lung cancer were recruited between January 2008 and December 2012 at Tangshan Gongren Hospital (Tangshan, China). The exclusive criteria included previous cancer and previous radiotherapy or chemotherapy. The controls were randomly selected from cancer-free individuals living in the same region during the same period as the cases were collected. The selection criteria included no prior history of cancer. Controls were frequency matched to the cases by age (±5 years) and sex. At recruitment, informed consent was obtained from each subject who was then interviewed for detailed information on demographic characteristics and lifetime history of tobacco use. The study was approved by Ethics Committee of Hebei United University (Approval No. 12--002).

Tag SNPs selection and genotyping {#Sec4}
---------------------------------

Based on the Han Chinese in Beijing (CHB) population data from HapMap database, we used Haploview 4.2 program to select candidate tag SNPs with an r^2^ threshold of 0.80 and minor allele frequency (MAF) greater than 1 %. For XAB2 gene, we extended the 5′- and 3′-untranslated regions (UTR) to include the 5′-UTR and 3′-UTR most SNP. As a result, 5 tagSNPs (2 in 5′ UTR, 2 in intron, 1 in exon region) in *XAB2* were included, which represent the common genetic variants in Chinese population. Genotyping was performed at Bomiao Tech (Beijing, China) using iPlex Gold Genotyping Asssy and Sequenom MassArray (Sequenom, San Diego, CA, USA). Sequenom's MassArray Designer was used to design PCR and extension primers for each SNP. The information on assay conditions and the primers are available upon request. Genotyping quality control consisted of no-temple control samples for allele peaks and verifying consistencies in genotype calls of 2 % randomly selected duplicate sample. In addition, we excluded individuals and SNPs based on genotyping quality (\<90 % call rate).

Statistical analysis {#Sec5}
--------------------

The *χ*2 test was used to examine differences in demographic variables and the distribution of genotype between patients and controls. Hardy-Weinberg equilibrium (HWE) for each SNP in controls was examined using Pearson goodness-of-fit *χ*2 test. The association of each tag SNP with the risk of NSCLC was estimated by odds ratios (ORs) and 95 % confidential intervals (95 % CI) using unconditional logistic regression adjusted by sex, age, and smoking status. Smokers were considered current smokers if they smoked up to 1 year before the date of cancer diagnosis for NSCLC patients or before the date of the interview for controls. The number of pack-years smoked was determined as an indication of cumulative cigarette-dose level \[pack-year = (cigarettes per day/20) × (years smoked)\]. Light and heavy smokers were categorized by using the 50th percentile pack-year value of the controls as the cut points (i.e., ≤25 and \>25 pack-years). Statistical analysis was performed using the SPSS version16.0 (SPSS Inc, Chicago, IL). A *P* value of \< 0.05 was considered as statistically significant. Gene-smoking interaction was analyzed by GxEscan (<http://biostats.usc.edu/software>).

Results {#Sec6}
=======

Subject characteristics {#Sec7}
-----------------------

The demographic characteristics of all participants are presented in Table [1](#Tab1){ref-type="table"}. The distribution of gender and age among NSCLC cancer cases and healthy controls were not significantly different (*P* = 0.832 for gender, and *P* = 0.470 for age). There were also no significant differences in the distribution of smoking status between cases and controls. However, the heavy smokers (≥25 pack-year) accounted for 63.4 % in cases and only 49.2 % in controls, which suggested that cigarette smoking was a prominent contributor to the risk of lung cancer. Among ever-smokers, 46,8 % (96) and 41.8 % (79) are former smokers in lung cancer cases and controls, respectively. Of 470 NSCLC patients, 37.9 % (178) were adenocarcinoma, 50.6 % (238) was squamous cell carcinoma, and 11.5 % (54) were other types, including large cell carcinoma (*n* = 49) and mixed cell carcinoma (*n* = 5).Table 1Distributions of select characteristics in cases and control subjectsVariablesCases (*n* = 470)Controls (*n* = 470)*P* value^a^No(%)No(%)Gender0.832 Male32468.932869.8 Female14631.114230.2Age0.470 \<508417.99620.4 50--5917737.718739.8 60--6912927.411123.6 ≥708017.07616.2Smoking status0.321 Non-smoker26556.428159.8 Ever-smoker20543.618940.2Pack-year smoked0.001 \<257536.69650.8 ≥2513063.49349.2^a^two-side *χ*2 test

Selected SNPs and risk of developing NSCLC {#Sec8}
------------------------------------------

The position and minor allele frequency (MAF) of the 5 selected tag SNPs in *XAB2* gene were presented in Table [2](#Tab2){ref-type="table"}. For all selected SNPs, the distributions of genotype frequencies in controls were close to those expected under Hardy Weinberg Equilibrium (HWE) (*P* \> 0.05 for all).Table 2Primary information of tag SNPs inXAB2geneGene and locusRs numberContig positionLocationBase changeMAF in controls*P* for HWE testCall rate (%)*XAB2*19p13.2rs41348162977475′ near geneT/C0.040.998100rs41348192972275′ near geneA/G0.500.70899.8rs794083295863IntronC/G0.330.157100rs4134860290403IntronT/C0.150.978100rs794078289839T620TG/A0.120.13697.8

The observed genotype frequencies in participants and the association of genotypes with the NSCLC were presented in Table [3](#Tab3){ref-type="table"}. Of all selected SNPs in *XAB2* genes, two SNPs were identified to be associated with the risk of NSCLC. For *XAB2* rs794078 G \> A polymorphism, we found that AA genotype carriers had a significantly decreased risk for developing NSCLC (OR = 0.12; 95 % CI = 0.03--0.54) in comparison to those with GG genotype. For *XAB2* rs4134816 T \> C polymorphism, just one CC genotype was found among all individuals, so we combined CT with CC genotype together for further analysis. Our data showed that the subjects with rs4134816 CT or CC genotype had a decreased risk of NSCLC compared with those carrying TT genotype with OR (95 % CI) of 0.46 (0.26--0.84). We didn't find that any other selected SNPs were associated with the risk of NSCLC.Table 3Genotype frequencies of *XAB2* and their association with non-small cell lung cancers*XAB2* GenotypesControls (*n* = 470)Cases (*n* = 470)*OR* (95 % *CI*)^a^*P* value^a^No(%)No(%)rs4134816  TT42991.345095.7  CT408.5204.30.49 (0.28--0.86)0.012  CC10.200.0NC CT + CC418.7204.30.46 (0.26--0.84)0.010rs4134819  AA12226.012626.8  AG22648.023750.40.96 (0.70--1.31)0.797  GG12226.010722.80.81 (0.56--1.16)0.251rs794083  CC22147.024953.0  CG18940.216134.20.72 (0.54--0.96)0.023  GG6012.86012.80.87 (0.58--1.31)0.517rs4134860  TT34172.633270.7  CT11825.112025.51.01 (0.75--1.36)0.962  CC112.3183.81.73 (0.80--3.75)0.163rs794078  GG36577.737479.6  AG9319.89420.00.97 (0.70--1.35)0.871  AA122.520.40.12 (0.03--0.54)0.006AG + AA10522.39620.40.87 (0.64--1.20)0.396^a^Data were calculated by logistic regression and adjusted for sex, age (categories), and smoking status

Stratification analysis of the *XAB2* polymorphisms and the risk of NSCLC {#Sec9}
-------------------------------------------------------------------------

We then performed stratification analysis to evaluate the effect of environmental factors on the association of *XAB2* polymorphisms with the risk of NSCLC (Table [4](#Tab4){ref-type="table"}). In dominant model, we found that the subjects carrying rs4134816 CC or CT genotype had a decreased risk for developing NSCLC among males with OR (95 % CI) of 0.39 (0.18--0.82), but not among females. When stratified by gender, we observed a positively significant interaction between rs4134816 genotypes and gender on decreasing NSCLC risk (*P* = 0.034). Our data also showed that younger subjects (age ≤ 60) with at least one C allele had a decreased risk of NSCLC with OR (95 % CI) of 0.35 (0.17--0.74), but older subjects didn't. However, there was no gene-environment interaction observed (*P* = 0.094). We didn't find that XAB2 4134816 C \> T variant effect on the risk of NSCLC when stratified by smoking status. The environmental factors, such as age, sex and smoking had no effect on the risk of NSCLC related to XAB2 genotypes at other polymorphic sites (Table [4](#Tab4){ref-type="table"}).Table 4Association of *XAB2* tagSNPs with NSCLC risk stratified by selected variablesGenetic VariantVariableGenotypes (Cases/Controls)Dominant model (AB + BB)/AA^b^*OR* (95 % *CI*)^a^*P* valueAA^b^AB + BB^b^rs4134816Sex  T \> C Male314/30110/270.39 (0.18--0.82)0.013 Female136/12810/140.68 (0.29--1.59)0.370Age ≤60251/25410/290.35 (0.17--0.74)0.006 \>60199/17510/120.98 (0.40--2.39)0.970Smoking status Non-smoker252/25613/240.51 (0.26--1.03)0.060 Ever-smoker198/1737/160.47 (0.19--1.20)0.113rs4134819Sex  A \> G Male80/90244/2381.10 (0.77--1.58)0.591 Female46/32100/1100.64 (0.38--1.09)0.098Age ≤6076/77185/2060.91 (0.63--1.33)0.638 \>6050/45159/1420.92 (0.57--1.48)0.726Smoking status Non-smoker82/75183/2060.81 (0.56--1.17)0.252 Ever-smoker44/47161/1421.13 (0.70--1.82)0.628rs794083Sex  C \> G Male169/159155/1690.88 (0.64--1.20)0.415 Female80/6266/800.66 (0.41--1.05)0.081Age ≤60139/140122/1430.90 (0.64--1.27)0.546 \>60110/8199/1060.71 (0.47--1.07)0.098Smoking status Non-smoker144/139121/1420.81 (0.58--1.14)0.226 Ever-smoker105/82100/1070.74 (0.49--1.11)0.141rs4134860Sex  T \> C Male227/23797/911.14 (0.80--1.61)0.470 Female105/10441/381.11 (0.66--1.87)0.702Age ≤60186/21175/721.24 (0.84--1.82)0.275 \>60146/13063/570.97 (0.63--1.51)0.906Smoking status Non-smoker190/20775/741.10 (0.76--1.61)0.608 Ever-smoker142/13463/551.05 (0.67--1.63)0.841rs794078Sex  G \> A Male256/25668/720.92 (0.63--1.35)0.673 Female118/10928/330.79 (0.45--1.40)0.426Age ≤60208/22653/571.04 (0.68--1.58)0.872 \>60166/13943/480.74 (0.46--1.20)0.226Smoking status Non-smoker211/22554/561.02 (0.67--1.55)0.930 Ever-smoker163/14042/490.73 (0.45--1.18)0.202^a^Data were calculated by unconditional logistic regression and adjusted for gender, age (categories), and smoking status, where it was appropriate^b^A stands for Major allele and B stands for Minor allele for each SNP

Discussion {#Sec10}
==========

In this case-control study in a Chinese population, we found that two tag SNPs (rs794078 and rs4134816) in *XAB2* were associated with significantly decreased risk of development non-small cell lung cancer. These findings indicated that *XAB2* genetic variants might contribute to the susceptibility of lung cancer.

Nucleotide excision repair is the main mechanism for removing the bulky DNA adduct from damage DNA for preventing carcinogens-induced mutagenesis \[[@CR22], [@CR23]\]. Several animal models, where individual NER genes were disrupted, had showed the importance of the integrity of NER pathway in preventing lung cancer \[[@CR24], [@CR25]\].

TC-NER, as one of important sub-pathways in NER, only repairs the lesions in the transcribed strand in active genes. There are several major proteins involved in TC-NER in human cells, including CSA, CSB, XPA and XAB2. Studies have showed that the deficient of these nucleotide excision repair proteins contributed to the risk of various cancers. Animal experiments showed that the CSB played an important role in the cellular response to stress and CSB^−/−^ mice were increased susceptible to chemically induced skin cancer \[[@CR26]\]. A case-control study also found 12.2 and 12.5 % reduced RNA transcriptional levels of CSA and CSB in lung cancer patients than controls \[[@CR27]\].

*XAB2* is a key factor in TC-NER, which is composed of 855 amino acids and contains 15 tetratricopeptide repeat motifs. By interacting with CSA, CSB, RNA polymerase II and XPA, XAB2 conducted the multiple functions in the process of transcription and TC-NER \[[@CR19], [@CR20]\]. Microinjection of specific antibodies against XAB2 inhibits transcription and TC-NER, suggesting the key role of XAB2 in the process of transcription and TC-NER \[[@CR20]\]. Knockdown of XAB2 in HeLa cell resulted in a hypersensitivity to killing by UV light and a decreased recovery of RNA synthesis \[[@CR19]\]. Over expression of XAB2 was observed in HL60 cells treated with inhibited all-trans retinoic acid (ATRA) and inhibited XAB2 expression by small interfering RNA (siRNA) increased ATRA-sensitive cellular differentiation, which indicated that XAB2 was associated with the cellular differentiation \[[@CR28]\].

Studies have demonstrated that the polymorphisms, which located in NER genes or regulatory sequences, may affect DNA repair capacity and further increase likelihood of cancer development. In the present study of NSCLC in Chinese, we used a relatively comprehensive selection of SNPs and found the significant effects of *XAB2* variants on the risk of lung cancer. This is the first study to investigate the association of *XAB2* polymorphisms with the risk for developing cancer. There were several studies to evaluate the role of *XAB2* genetic variants in complex autoimmune disease. For example, Briggs et al. conducted a case-control study to evaluate the correlation between *XAB2* rs4134860 T \> C variant and the risk of multiple sclerosis (MS) and found an increased risk of MS among rs4134860 CC genotype carriers \[[@CR29]\]. In this lung cancer case-control study, we didn't find any association of *XAB2* rs4134860 T \> C polymorphism with the risk of NSCLC. In another study, researchers analyzed the impact of several polymorphisms in DNA repair genes on the prognosis of colorectal cancer patients and didn't find the association of *XAB2* rs794078 G \> A variant with the cancer prognosis \[[@CR30]\]. In present study, individuals carrying *XAB2* rs794078 AA genotype had 88 % decreased risk of NSCLC.

As we know, the magnitude of the effect of smoking far outweighed all other factors leading to lung cancer \[[@CR31], [@CR32]\]. Many studies have demonstrated that the strong association of smoking with lung cancer risk \[[@CR5], [@CR33], [@CR34]\]. Therefore, we further analyzed the role of *XAB2* polymorphisms in the development of NSCLC stratified by smoking status. We observed that a 49 % protective effect for *XAB2* rs4134816 variant was evident only for non-smokers, but not for smokers. The exact mechanism of how cigarette-smoking effects on DNA repair capacity posted by *XAB2* polymorphism is unknown. One possible explanation may be that the protective effect of *XAB2* variant allele might be evident in non-smokers with low levels of oxidative damage. Similar pattern of genetic effects have been observed for DNA repair gene XRCC1 (X-ray repair cross-complementation group 1) at low smoking exposure, but not at high smoking exposure \[[@CR35]\].

When stratified by gender, our study showed a 61 % protective effect of *XAB2* rs4134816 C genotype among men, but not among women. Genetic variants in NER genes are associated with variability of lung cancer risk. Letkova and his colleagues investigated the polymorphisms of selected DNA repair genes, including XPC, XPD, hOGG1 and XRCC1, and found the different risks of developing lung cancer when stratified by gender, which further supporting our current findings \[[@CR36]\]. Our present study also found that a 65 % protective effect for *XAB2* rs4134816 T \> C genetic variant among subjects aged 60 years or younger. Using Cox proportional hazard model, Gauderman et al. estimated the age-specific genetic incidence rate and found that the estimated proportion of lung cancer patients with high-risk allele exceeds 90 % for cases with onset at age 60 years or less and decreases to approximately 10 % for cases with onset at age 80 years or older. These findings suggested the contribution of age in the development of cancer \[[@CR37]\]. The numbers of subjects in several of subgroups were very small, so some caution is needed when interpreting these findings.

Our study has its limitation. Due to the moderate sample size and the lack of related phenotypic and functional assays, large studies and functional evaluations are still need to be conducted in the future.

Conclusions {#Sec11}
===========

In conclusion, we have genotyped 5 tag SNPs in *XAB2* gene in this NSCLC case-control set. We found the evidence of significant association with the risk of NSCLC for two tag SNPs (rs794078 and rs4134816) in *XAB2* gene in Chinese population. These results further supported that *XAB2* play a significant role in the development of NSCLC.
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